Eric Devroe - 14 Nov 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Operating Officer
Signature
/s/ Adam D. Levy, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
14 Nov 2025
Transactions value $
-$1,373
Form type
4
Filing time
18 Nov 2025, 16:29:50
Previous filing
18 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Devroe Eric Chief Operating Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact 18 Nov 2025 0001950573

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability -$1.37K -613 -0.93% $2.24 65.3K 14 Nov 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.